New PET/MRI scan aims to find hidden brain tumor cells

NCT ID NCT05632562

Recruiting now Diagnosis Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests a new type of PET/MRI scan that uses special radioactive tracers to detect leftover high grade glioma (a fast-growing brain cancer) after standard radiation therapy. About 20 patients aged 10 and older will receive up to three imaging sessions. The goal is to see if the scan can find active tumor that standard imaging might miss, and to develop a workflow for future use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) and 1H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole (FMISO) radioactive tracers
What this could lead to: If successful, this imaging method could help doctors better detect leftover tumor after standard treatment, potentially guiding more personalized care.
What could go wrong: This is a very early feasibility study with only 20 participants, so results may not apply widely. The scan is experimental and not yet proven to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH GRADE GLIOMA

Contacts and locations

Locations

UAB
NOT_YET_RECRUITING

Birmingham, Alabama, 35249, United States
UAB
RECRUITING

Birmingham, Alabama, 35249, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.